Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression
Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Loma Linda, California 92354, United States
Sacramento, California 95817, United States
San Francisco, California 94115, United States
Chicago, Illinois, United States
Charleston, South Carolina 29425, United States
Memphis, Tennessee 38104, United States
Nashville, Tennessee 37212-1375, United States
Houston, Texas 77030, United States
Seattle, Washington 98104, United States
Seattle, Washington 98195, United States
Spokane, Washington 99204, United States
Ciudad Autonoma de Buenos Aires, Buenos Aires 1093, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires 1425, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1118AAT, Argentina
Mendoza, Buenos Aires M5501ACJ, Argentina
Cardoba, Córdoba Province 5016, Argentina
CABA, 1425, Argentina
Le Kremilin Bicretre, 942875, France
Toensberg Norge, 3103, Norway